Search results
Showing 136 to 150 of 1127 results for criteria
Awaiting development Reference number: GID-TA11911 Expected publication date: TBC
Luspatercept for Anaemia due to myelodysplastic syndromes [TSID12310]
Awaiting development Reference number: GID-TA11914 Expected publication date: TBC
Orforglipron for treating obstructive sleep apnoea associated with obesity or overweight [TSID12323]
Awaiting development Reference number: GID-TA11916 Expected publication date: TBC
Ravulizumab for treating primary IgA nephropathy [TSID12313]
Awaiting development Reference number: GID-TA11919 Expected publication date: TBC
Awaiting development Reference number: GID-TA11921 Expected publication date: TBC
Belzutifan for treating advanced pheochromocytoma or paraganglioma [TSID12304]
Awaiting development Reference number: GID-TA11928 Expected publication date: TBC
Awaiting development Reference number: GID-TA11929 Expected publication date: TBC
Riliprubart for treating chronic inflammatory demyelinating polyneuropathy [TSID12314]
Awaiting development Reference number: GID-TA11917 Expected publication date: TBC
Awaiting development Reference number: GID-TA11932 Expected publication date: TBC
Awaiting development Reference number: GID-TA11933 Expected publication date: TBC
Zasocitinib for treating moderate to severe plaque psoriasis [ID6700]
Awaiting development Reference number: GID-TA11926 Expected publication date: TBC
Epcoritamab + R-CHOP for Diffuse large B-cell lymphoma [ID6701]
Awaiting development Reference number: GID-TA11935 Expected publication date: TBC
Luspatercept for treating anaemia caused by myelofibrosis [ID6697]
Awaiting development Reference number: GID-TA11915 Expected publication date: TBC
This guideline covers the period before, during and after a young person moves from children's to adults' services. It aims to help young people and their carers have a better experience of transition by improving the way it’s planned and carried out. It covers both health and social care.
Lenvatinib for untreated advanced hepatocellular carcinoma (TA551)
Evidence-based recommendations on lenvatinib (Lenvima) for untreated advanced hepatocellular carcinoma in adults.